Opportunity Information: Apply for PAR 06 341
Apply for PAR 06 341
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Innovative Therapies and Clinical Studies for Screenable Disorders (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173 Research Related to Deafness and Communication Disorders 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Apr 10, 2006.
- Applicants must submit their applications by Jan 7, 2010 Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: City or township governments Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education County governments Native American tribal governments (Federally recognized) Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses State governments Independent school districts Small businesses Others (see text field entitled Additional Information on Eligibility for clarification).
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government are eligible to apply. Faith based or community based organizations
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Innovative Therapies and Clinical Studies for Screenable Disorders (R03) opportunity (Funding Opportunity Number PAR-06-341) is an NIH discretionary grant announcement led by three institutes: the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute on Deafness and Other Communication Disorders (NIDCD), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Its central purpose is to fund research that improves the basic understanding of diseases already included in screening programs and, just as importantly, supports the development of therapeutic interventions for genetic conditions that could realistically become screenable in the near future. A key idea in this announcement is the definition of a "high priority condition": it refers to a disorder that is not necessarily screened today, but could become appropriate for newborn screening if an effective therapy exists. In other words, the FOA is trying to help move conditions across the threshold from "diagnosable" to "actionable," because screening is most valuable when early detection leads to an intervention that changes outcomes.
The scientific scope is intentionally broad because the research needs can vary widely depending on the disorder, the state of existing knowledge, and the maturity of potential treatments. Projects may focus on foundational biological understanding that directly informs therapy development, as well as early clinical studies that help establish whether interventions are feasible, safe, or potentially effective. Because the work could range from small proof-of-concept studies to focused early-stage therapeutic development questions, the NIH notes that the size and duration of awards may differ across applications, and the total number of awards will depend on the volume, quality, and budgets of applications received.
This particular announcement uses the NIH Small Research Grant (R03) mechanism, which is designed for smaller, tightly scoped projects that can be completed relatively quickly with limited resources. The R03 mechanism is not renewable, reinforcing its role as a springboard for generating preliminary data, testing a targeted hypothesis, piloting methods, or completing a discrete piece of work that can set the stage for a larger application later. This FOA runs in parallel with two other announcements that share the same scientific scope but use larger mechanisms: an R21 (PAR-06-342), which supports exploratory/developmental research, and an R01 (PAR-06-060), which supports full-scale research projects.
Funding limits under the R03 are clearly defined. Applicants may request up to $50,000 per year in direct costs for a project period of up to two years, with a maximum of $100,000 in direct costs across the entire two-year period. There is no cost sharing or matching requirement. The funding activity categories and CFDA numbers linked to the participating institutes include 93.173 (deafness and communication disorders), 93.847 (diabetes, digestive, and kidney diseases extramural research), and 93.865 (child health and human development extramural research), reflecting the wide range of screened and potentially screenable conditions that could fit the initiative.
Eligibility is broad and includes both for-profit and nonprofit entities, public or private organizations, and a wide range of institutional types such as universities, colleges, hospitals, laboratories, and government units at the state and local level. Importantly, the announcement also allows applications from eligible federal agencies and explicitly states that foreign institutions are eligible to apply. Faith-based and community-based organizations may also be eligible, and the listing of eligible applicants includes various government entities (for example, city or township governments, county governments, special district governments, independent school districts), tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and nonprofits with or without 501(c)(3) status (with noted distinctions in the eligibility listing). The emphasis on broad eligibility suggests NIH’s intent to encourage participation from diverse research environments, including those that may have unique access to patient populations, screening programs, or specialized expertise.
The opportunity is open to any qualified Project Director/Principal Investigator with the skills, knowledge, and resources to carry out the proposed work, working through their institution to submit an application. NIH also reiterates its longstanding encouragement for individuals from underrepresented racial and ethnic groups and individuals with disabilities to apply. Applicants may submit more than one application as long as each proposed project is scientifically distinct, which can be useful for teams pursuing multiple, clearly separated lines of investigation related to different disorders or different therapeutic strategies.
Administratively, the FOA was posted April 10, 2006, with multiple receipt dates and a closing timeline that extended through January 7, 2010, with an archive date of February 7, 2010. The full announcement was available through NIH at the provided link (grants.nih.gov). For access or technical issues, the contact listed is the NIH Office of Extramural Research (OER) webmaster.
Frequently Asked Questions (FAQs)
What is the funding opportunity name and number?
The opportunity is titled Innovative Therapies and Clinical Studies for Screenable Disorders (R03). The Funding Opportunity Number is PAR-06-341.
Which NIH institutes lead this grant announcement?
This discretionary NIH grant announcement is led by three institutes: the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute on Deafness and Other Communication Disorders (NIDCD), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
What is the central purpose of this FOA?
The central purpose is to fund research that improves the basic understanding of diseases already included in screening programs and to support development of therapeutic interventions for genetic conditions that could realistically become screenable in the near future.
What does the FOA mean by a "high priority condition"?
A "high priority condition" is defined as a disorder that may not be screened today, but could become appropriate for newborn screening if an effective therapy exists. The FOA is focused on helping move conditions from being merely diagnosable to being actionable, where early detection can lead to an intervention that changes outcomes.
What kinds of research projects are within the scientific scope?
The scope is intentionally broad. Projects may include foundational biological research that directly informs therapy development, as well as early clinical studies that help determine whether interventions are feasible, safe, or potentially effective. The FOA anticipates work ranging from small proof-of-concept studies to focused early-stage therapeutic development questions.
Is this opportunity focused only on disorders already included in screening programs?
No. It includes disorders already included in screening programs, and it also supports therapy development for genetic conditions that could become screenable in the near future, especially where having an effective therapy would make screening more appropriate.
What grant mechanism does this announcement use?
This announcement uses the NIH Small Research Grant (R03) mechanism, which is intended for smaller, tightly scoped projects that can be completed relatively quickly with limited resources.
Is the R03 award renewable under this FOA?
No. The R03 mechanism is not renewable, reflecting its role as a springboard for generating preliminary data, piloting methods, testing a targeted hypothesis, or completing a discrete piece of work that can support a later, larger application.
Are there related announcements with the same scientific scope but different mechanisms?
Yes. This FOA runs in parallel with two other announcements that share the same scientific scope: an R21 (PAR-06-342) for exploratory/developmental research, and an R01 (PAR-06-060) for full-scale research projects.
What is the maximum budget allowed for this R03?
Applicants may request up to $50,000 per year in direct costs for a project period of up to two years, with a maximum of $100,000 in direct costs across the entire two-year period.
What is the maximum project period for an award?
The maximum project period is up to two years.
Is there a cost sharing or matching requirement?
No. The FOA states there is no cost sharing or matching requirement.
How many awards will NIH make under this announcement?
The NIH indicates that the number of awards will depend on the volume, quality, and budgets of the applications received.
What CFDA numbers are associated with the participating institutes?
The CFDA numbers referenced include 93.173 (deafness and communication disorders), 93.847 (diabetes, digestive, and kidney diseases extramural research), and 93.865 (child health and human development extramural research).
Who is eligible to apply?
Eligibility is broad and includes for-profit and nonprofit entities, public or private organizations, and institutional types such as universities, colleges, hospitals, laboratories, and state and local government units. The FOA also allows applications from eligible federal agencies and explicitly states that foreign institutions are eligible.
Are faith-based and community-based organizations eligible?
Yes. The FOA notes that faith-based and community-based organizations may also be eligible.
What types of government entities are included in the eligibility listing?
The eligibility listing includes various government entities such as city or township governments, county governments, special district governments, independent school districts, tribal governments and tribal organizations, and public housing authorities/Indian housing authorities.
Are nonprofits without 501(c)(3) status allowed to apply?
The eligibility listing includes nonprofits with or without 501(c)(3) status (with distinctions noted in the eligibility list), indicating that both categories can be eligible under the FOA as described.
Who can serve as the Project Director/Principal Investigator (PD/PI)?
The opportunity is open to any qualified PD/PI with the skills, knowledge, and resources to carry out the proposed work, submitting an application through their institution.
Does NIH encourage applications from underrepresented groups?
Yes. NIH reiterates its longstanding encouragement for individuals from underrepresented racial and ethnic groups and individuals with disabilities to apply.
Can an applicant submit more than one application to this FOA?
Yes. Applicants may submit more than one application, as long as each proposed project is scientifically distinct.
When was this FOA posted, and what is the overall timeline provided?
The FOA was posted on April 10, 2006. It had multiple receipt dates and a closing timeline that extended through January 7, 2010, with an archive date of February 7, 2010.
Where was the full announcement made available?
The full announcement was available through NIH at the referenced link on grants.nih.gov.
Who is listed as the contact for access or technical issues?
For access or technical issues, the contact listed is the NIH Office of Extramural Research (OER) webmaster.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Exploratory Grants for Behavioral Research in Cancer Control (R21)
Previous opportunity: Innovative Therapies and Clinical Studies for Screenable Disorders (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 06 341
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 06 341) also looked into and applied for these:
| Funding Opportunity |
|---|
| Shared Neurobiology of Fragile X Syndrome and Autism (R03) Apply for PA 06 429 Funding Number: PA 06 429 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Shared Neurobiology of Fragile X Syndrome and Autism (R21) Apply for PA 06 430 Funding Number: PA 06 430 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Educational Programs for Population Research (R25) Apply for PA 06 507 Funding Number: PA 06 507 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Transmission of Human Immunodeficiency Virus (HIV) In Semen (R01) Apply for PA 07 044 Funding Number: PA 07 044 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Collaborative Research for Molecular and Genomic Studies of Basic Behavior in Animal Models (R01) Apply for PA 07 096 Funding Number: PA 07 096 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Innovative Therapies and Clinical Studies for Screenable Disorders (R01) Apply for PAR 07 184 Funding Number: PAR 07 184 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Vulvodynia Systematic Epidemiologic, Etiologic Or Therapeutic Studies (R01) Apply for PA 07 182 Funding Number: PA 07 182 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research in Eating Disorders (R01) Apply for PA 07 285 Funding Number: PA 07 285 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Fragile X Pre mutation and Ovarian Function (R01) Apply for PA 07 219 Funding Number: PA 07 219 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Fragile X Pre mutation and Ovarian Function (R03) Apply for PA 07 220 Funding Number: PA 07 220 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Multidisciplinary Translational Research in Critical Care (R01) Apply for PA 07 233 Funding Number: PA 07 233 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| International Extramural Associates Research Development Awards (IEARDA) (G11) Apply for PAR 07 431 Funding Number: PAR 07 431 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Interdisciplinary Research on Implantation (R01) Apply for PA 07 445 Funding Number: PA 07 445 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21) Apply for PAR 07 446 Funding Number: PAR 07 446 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R03) Apply for PAR 07 447 Funding Number: PAR 07 447 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Role of Adipose Tissue as an Endocrine Organ in Reproduction and Infertility (R01) Apply for PA 08 059 Funding Number: PA 08 059 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Role of Adipose Tissue as an Endocrine Organ in Reproduction and Infertility (R21) Apply for PA 08 060 Funding Number: PA 08 060 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Extramural Associates Research Development Award (EARDA) (G11) Apply for PAR 08 096 Funding Number: PAR 08 096 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Mechanisms of Functional Recovery After Stroke (R01) Apply for PA 08 099 Funding Number: PA 08 099 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Mechanisms of Functional Recovery After Stroke (R21) Apply for PA 08 100 Funding Number: PA 08 100 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 06 341", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.